Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Gross Margin (2018 - 2025)

10x Genomics (TXG) has disclosed Gross Margin for 8 consecutive years, with 68.09% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 85.0% to 68.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.05% through Dec 2025, up 119.0% year-over-year, with the annual reading at 69.05% for FY2025, 119.0% up from the prior year.
  • Gross Margin hit 68.09% in Q4 2025 for 10x Genomics, up from 67.32% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 95.76% in Q2 2021 to a low of 62.18% in Q3 2023.
  • Historically, Gross Margin has averaged 73.05% across 5 years, with a median of 71.25% in 2025.
  • Biggest five-year swings in Gross Margin: skyrocketed 1919bps in 2021 and later crashed -1993bps in 2022.
  • Year by year, Gross Margin stood at 80.77% in 2021, then dropped by -5bps to 76.43% in 2022, then dropped by -18bps to 62.93% in 2023, then rose by 7bps to 67.24% in 2024, then grew by 1bps to 68.09% in 2025.
  • Business Quant data shows Gross Margin for TXG at 68.09% in Q4 2025, 67.32% in Q3 2025, and 72.34% in Q2 2025.